Phase 3 studies confirm long-term disease control with ruxolitinib cream in atopic dermatitisDecember 19, 2022Atopic Dermatitis
Meta-analysis supports safe use of topical calcineurin inhibitors in ADDecember 19, 2022Atopic Dermatitis
Dermatology NewsDupilumab significantly improves markers of AD severity in pediatric patientsDecember 15, 2022PediatricsAtopic Dermatitis
Dermatology NewsParental atopic dermatitis, asthma linked to risk of AD in offspringDecember 9, 2022Atopic DermatitisPediatrics
Dermatology NewsPooled safety data analysis of tralokinumab reportedDecember 8, 2022Atopic Dermatitis
Dermatology NewsSaururus chinensisDecember 8, 2022Aesthetic DermatologyMelasmaPigmentation DisordersAtopic Dermatitis
Janus Kinase Inhibitors in the Treatment of Atopic Dermatitis: Military ConsiderationsDecember 7, 2022Atopic Dermatitis
Dermatology NewsBrepocitinib improves symptoms of mild to moderate AD in phase 2b trialNovember 28, 2022Atopic Dermatitis
Dermatology NewsConsider gaps in access and knowledge in diagnosis and treatment in skin of colorNovember 28, 2022Diversity in MedicinePsoriasisMelanomaRosaceaAcneAtopic DermatitisPediatrics
Dupilumab as a Therapeutic Approach in Alopecia UniversalisNovember 21, 2022Hair & NailsAtopic Dermatitis
Proactive TCS fails to reduce relapse rate in moderate-to-severe atopic dermatitisNovember 18, 2022Atopic Dermatitis
